MedTrace Logo

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

NCT00785941 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-10-13

No results posted yet for this study

Summary

The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.

Conditions

Interventions

BIOLOGICAL

IMC-A12

Cohort 1 6 mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

IMC-A12

Cohort 2 10 mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

IMC-A12

Cohort 3 15 mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

IMC-A12

Cohort 4 21 mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

IMC-A12

Cohort 5 27 mg/kg I.V., once every other week for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • E-mail: ClinicalTrials@ ImClone.com · Eli Lilly and Company

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-10-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785941 on ClinicalTrials.gov